Analysts Are Updating Their OneSource Specialty Pharma Limited (NSE:ONESOURCE) Estimates After Its First-Quarter Results
NiveshIQ
NSE: ONESOURCE · Pharma
Onesource Specialty Pharma Ltd.
₹1,749.70▲ ₹18.40 (+1.06%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on ONESOURCE. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Onesource Specialty Pharma Ltd.
OneSource Specialty Pharma Limited is a biopharmaceutical company that engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats across India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services, as well as drug-devices, sterile injectables, soft gelatin capsules, and biologics solutions. Its recent Q1FY27 results showed strong growth, driven by semaglutide and biologics, with revenue and margin gains. The company's capacity expansion and commercial launches have supported robust FY 2028 guidance. OneSource Specialty Pharma has established a strong competitive position in the biopharmaceutical market, with a diversified prod
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹172.00 Cr +341.00% | ₹1,445 Cr +740.10% | ₹1,422 Cr -1.60% |
| EBITDA Margin | -31.90% | 32.25% | 22.46% |
| Net Profit | -95.10% | ||
| EPS | – | ₹2.59 | ₹-6.44 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Analysts Are Updating Their OneSource Specialty Pharma Limited (NSE:ONESOURCE) Estimates After Its First-Quarter Results
OneSource Specialty Pharma Ltd (BOM:544292) Q1 2027 Earnings Call Highlights: Robust Growth and ...
🔒
+ 3 more stories about Onesource Specialty Pharma Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹449 Cr, PAT ₹25 Cr, EPS ₹2.18, EBITDA margin 28.3%. Growth context: revenue QoQ +4.9%, PAT QoQ +443.5%.
Management commentary highlights the significance of product launches, approvals, and therapy-mix improvement, along wit...
FY26 (last completed FY): revenue ₹1, 422 Cr, PAT ₹-74 Cr, EBITDA margin 22.5%, EPS ₹-6.44. Year-on-year: revenue YoY -1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for ONESOURCE
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track ONESOURCE alongside your other holdings
Unlock full ONESOURCE research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Onesource Specialty Pharma Ltd.?
NiveshIQ detects active intelligence signals for Onesource Specialty Pharma Ltd. (ONESOURCE) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Onesource Specialty Pharma Ltd.?
Onesource Specialty Pharma Ltd. operates in the Pharma sector with a market capitalisation of ₹2,118,596.2L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.